Filtered By:
Source: Internal and Emergency Medicine
Condition: Bleeding
Drug: Clopidogrel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry
AbstractOptimal dual antiplatelet therapy (DAPT) strategy in high-bleeding risk (HBR) patients presenting with acute coronary syndrome remains debated. We sought to investigate the use of clopidogrel versus ticagrelor in HBR patients with acute coronary syndrome and their impact on ischemic and bleeding events at 1 year. In the START-ANTIPLATELET registry (NCT02219984), consecutive patients with ≥ 1 HBR criteria were stratified by DAPT type in clopidogrel versus ticagrelor groups. The primary endpoint was net adverse clinical endpoints (NACE), defined as a composite of all-cause death, myocardial infarct ion, stroke,...
Source: Internal and Emergency Medicine - June 14, 2020 Category: Emergency Medicine Source Type: research
